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S74 ABSTRACTSResults: A total of 298 patients were identified, of which 270 patients
were diagnosed with Invasive ductal Carcinoma (IDC), and 28 with inva-
sive lobular carcinoma (ILC).
The Chi-squared test was used to analyse data, and a strong statistically
significant relationship was found between LVI and sentinel node positiv-
ity (p<0.001) for all patients observed in this study.
There was also a statistically significant association between LVI in
core biopsy tissue and IDC overall, and was particularly so for Grade 2
and 3 (p<0.001). This strong association remains so even after adjusting
for tumour size.
Conclusions: Our study suggests that a subgroup of breast cancer pa-
tients with Grade 2 and 3 IDC, could be offered Axillary lymph node clear-
ance on the basis of LVI in their pre-operative core biopsy. Further large
scale prospective studies are required to substantiate our findings and
also to fully assess the link for ILC of all grades with LVI.
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Background: High intensity focused ultrasound HIFU) is a non-inva-
sive technique that may be used for the treatment of breast lesions. For
breast cancer, it has the potential to improve cosmetic outcomes and allow-
ing earlier administration of systemic therapies due to shorter postopera-
tive recovery times. This systematic review evaluates the current
evidence on outcomes (cosmetic, imaging and/or histopathology) of
HIFU in the management of breast cancer.
Material and Methods: All studies published up to December 2013
evaluating the role of HIFU in the treatment of breast cancers were iden-
tified using Medline/PubMed library databases. Studies were considered
suitable if they were performed on human subjects with breast cancers
and objectively recorded at least one clinical outcome measure of response
(imaging, histopathological and/or cosmetic) to HIFU treatment.
Results: A total of nine studies fulfilled the inclusion criteria. No re-
sidual tumour was found in 46% (55/119, range 17-100%), less than
10% residual tumour in 29% (35/119, range 0-53%), and between 10-
90% residual tumour in 23% (27/119, range 0-60%) of patients who under-
went surgical excision after HIFU treatment. Pain was the most common
complication associated with HIFU (40%). Less frequent complications
were oedema (17%), skin burns (4%) and pectoralis major injury (4%).
Magnetic resonance images (MRI) reported post-treatment absence of
contrast enhancement in 82% of patients (31/38 patients, range 50-
100%) indicative of coagulative necrosis. Correlation with the amount of
enhancement visible on pre- and post-treatment MRI was able to success-
fully predict the presence of residual disease.
Conclusions: HIFU has been shown to successfully induce coagulative
necrosis in breast cancer. Large prospective trials are needed to demon-
strate consistent tumour and margin necrosis (oncological safety) with reli-
able follow-up imaging.
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Background: With the widespread concept of sentinel lymph node
(SN), axillary dissection is now only performed in limited cases, even in
cases with SN metastasis, exploring the possibility of avoiding radical
dissection. Based on the results of a retrospective observational study in
patients who had been treated at a single institution with a consistent ther-
apeutic strategy, we discuss the long-term prognosis of sentinel lymph
node-positive breast cancer patients without dissection.
Materials and Methods: The subjects comprised patients with cT1-
3N0 invasive breast cancer, who had undergone SN biopsy (SNB) during
the period from May 2003 to February 2014. Patients with bilateral breast
cancer and those who had undergone SNB before preoperative treatment
were excluded. Intraoperative diagnosis was conducted by imprint
cytology with serial sectioning at 2 mm intervals. Patients diagnosed
with SN (+) underwent axillary dissection. Permanent pathological diag-
nosis was conducted using combined cytokeratin immune histochemistry.
In principle, patients were recommended to undergo axillary dissection if
they were found to be positive for metastasis. However, many cases were
followed up with observation without undergoing dissection under the suit-
able systemic therapy.
Results: SNB was performed in 1323 patients. During the intraopera-
tive diagnosis, 233 cases were diagnosed with SN (+) and 1090 cases with
SN (-). Of the SN (+) cases, 227cases underwent additional axillary level 1
and level 2 dissection or dissection for sampling. Permanent diagnosis
demonstrated macrometastasis in 204 cases, micrometastasis in 11 cases
and ITC in 5 cases, no metastasis in 7 cases. The permanent pathological
diagnosis of patients with SN (-) was a definite diagnosis of pN0 in 995
cases and pN1 in 95 cases (8.7%). Breakdown of the 95 cases was macro-
metastasis in 57 cases (60%) and micrometastasis in 38 cases. However,
additional dissection was only performed in 1 case and the other 94 cases
were followed up by observation. Median follow-up period was 67.5
months. Axillary recurrence was observed in: group(A) 4 of the 995 intra-
operative-SN (-) pN0cases (0.4%), group(B) 3 of the 94 intraoperative-SN
(-)-pN1 non-dissection cases (3.2%) and group(C) 1 of the 227 intraoper-
ative-SN (+) dissection cases(0.4%). Distant recurrence was observed in:
(A) 55/995 cases (5.5%), (B) 11/94cases (11.7%) and (C) 42/227 cases
(18.5%). With regard to (B) and(C), macrometastasis was found in (B)
7/56 cases (12.5%) and (C) 39/204 cases(19.1%) and micrometastasis in
(B) 4/38 cases (10.5%) and (C) 1/11 cases(9.1%), respectively. Deaths
were reported in: (A) 23/995 cases (2.3%), (B)3/94 cases (3.2%) and (C)
20/227 cases (8.8%), respectively.
Conclusions: In cases in whom dissection was omitted, no increase in
axillary recurrence was observed, and the long-term prognosis of these pa-
tients was comparable to that of patients who underwent dissection. It was
suggested that it is possible to control the axillary lymph node area locally
with systemic treatment and that there is no significance of adhering to
dissection.
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